Profile of patients treated with omalizumab in routine clinical practice in Spain

Allergologia et Immunopathologia

Volumn 42, Issue 2, 2014, Pages 102-108

  Ancochea, J ^a   Chivato, T ^b   Casan, P ^c   Picado, C ^d   Herraez L ^e   Casafont, J ^e  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b HOSPITAL CENTRAL DE LA DEFENSA GÓMEZ ULLA   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e Unidad de Health Outcomes Research   (Spain)

Author keywords

Anti IgE; Effectiveness; Observational study; Omalizumab; Uncontrolled severe allergic asthma

Indexed keywords

ANTIASTHMATIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; GLUCOCORTICOID; IMMUNOGLOBULIN E; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; OMALIZUMAB; ANTIIDIOTYPIC ANTIBODY; MONOCLONAL ANTIBODY;

ADULT; ALLERGIC ASTHMA; ARTICLE; ASTHMA CONTROL QUESTIONNAIRE; ASTHMA QUALITY OF LIFE QUESTIONNAIRE; CLINICAL PRACTICE; CORTICOSTEROID THERAPY; DISEASE COURSE; DISEASE EXACERBATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; QUALITY OF LIFE INDEX; QUESTIONNAIRE; RETROSPECTIVE STUDY; SEVERE ALLERGIC ASTHMA; SPAIN; TREATMENT OUTCOME; ASTHMA; CLINICAL TRIAL; COMPLICATION; HYPERSENSITIVITY; MULTICENTER STUDY;

ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; FEMALE; HUMANS; HYPERSENSITIVITY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SPAIN; TREATMENT OUTCOME;

EID: 84897025976     PISSN: 03010546     EISSN: 15781267     Source Type: Journal    
DOI: 10.1016/j.aller.2012.10.010     Document Type: Article

References (31)

1. Masoli M., Fabian D., Holt S., Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004, 59:469-478.
2. Rea H.H., Scragg R., Jackson R. A case-control study of deaths from asthma. Thorax 1986, 41:833-839.
3. Hartert T.V., Speroff T., Togias A., Mitchel E.F., Snowden M.S., Dittus R.S., et al. Risks factors for recurrent asthma hospital visits and death among a population of indigent older adults with asthma. Ann Allergy Asthma Immunol 2002, 89:467-473.
4. Global Strategy for Asthma Management and Prevention (Updated 2010). Global Initiative for Asthma (GINA). URL:. http://www.ginasthma.org/.
5. Bateman E.D., Boushey H.A., Bousquet J., Busse W.W., Clark T.J., Pauwels R.A., et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am J Respir Crit Care Med 2004, 170:836-844.
6. Rabe K.F., Adachi M., Lai C.K., Christopher K.W., Soriano J.B., Vermeire P.A., et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 2004, 114:40-47.
7. Rabe K.F., Vermiere P.A., Soriano J.B., Maler W.C. Clinical management of asthma in 1999. The asthma insights and reality in Europe (AIRE) Study. Eur Respir J 2000, 16:802-807.
8. Price D. The use of omalizumab in asthma. Prim Care Respir J 2008, 17:62-72.
9. Fueyo A., Ruiz M.A., Ancochea J., Guilera M., Badia X. Asthma control in Spain. Do season and treatment pattern matter? The ESCASE study. Respir Med 2007, 101:919-924. ESCASE Group.
10. Dockrell M., Partridge M.R., Valovirta E. The limitations of severe asthma: the results of a European survey. Allergy 2007, 62:134-141.
11. Holgate S.T., Polosa R. The mechanisms, diagnosis, and management of severe asthma in adults. Lancet 2006, 368:780-793.
12. Owen C.E. Anti-immunoglobulin E therapy for asthma. Pulm Pharmacol Ther 2002, 15:417-424.
13. Holgate S.T., Djukanović R., Casale T., Bousquet J. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy 2005, 35:408-416.
14. Humbert M., Beasley R., Ayres J., Slavin R., Hébert J., Bousquet J., et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005, 60:309-316.
15. Buhl R., Hanf G., Soler M., Bensch G., Wolfe J., Everhard F., et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J 2002, 20:1088-1094.
16. Holgate S.T., Chuchalin A.G., Hébert J., Lötvall J., Persson G.B., Chung K.F., et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004, 34:632-638.
17. Busse W., Corren J., Lanier B.Q., McAlary M., Fowler-Taylor A., Cioppa G.D., et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001, 108:184-190.
18. Solèr M., Matz J., Townley R., Buhl R., O'Brien J., Fox H., et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001, 18:254-261.
19. Chipps B., Buhl R., Beech K.M., Fox H., Thomas K., Reisner C. Improvement in quality of life with omalizumab in patients with severe allergic asthma. Curr Med Res Opin 2006, 22:2201-2208.
20. Pacheco-Galván A., Hinojosa-Macías M., Hurtado-Barbudo B., González-Cervera J., Sueiro-Bendito A. Analysis of asthma control and quality of life in severe allergic asthmatics under treatment with anti-IgE, omalizumab. Med Clin (Barc) 2009, 133:460-463.
21. Domingo C., Pomares X., Sancho M., Veigas C., Moreno A., Belmonte Y., et al. Efectividad y tolerancia de omalizumab en asma grave. Arch Bronconeumol 2008, 44(Espec Congre):5.
22. Vennera M.C., Bartra J., Muñoz R., Valero A., Fontana A., Picado C. Omalizumab en el tratamiento del asma grave: experiencia clínica y primeros resultados. Arch Bronconeumol 2008, 44(Espec Congre):10-11.
23. Juniper E.F., O'Byrne P.M., Guyatt G.H., Ferrie P.J., King D.R. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999, 14:902-907.
24. Juniper E.F., Buist A.S., Cox F.M., Ferrie P.J., King D.R. Validation of a standardized version of the Asthma Quality of Life Questionnaire. Chest 1999, 115:1265-1270.
25. Molimard M., de Blay F., Didier A., Le Gros V. Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France. Respir Med 2008, 102:71-76.
26. Korn S., Thielen A., Seyfried S., Taube C., Kornmann O., Buhl R. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. Respir Med 2009, 103:1725-1731.
27. Brusselle G., Michils A., Louis R., Dupont L., Van de Maele B., Delobbe A., et al. "Real-Life" effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study. Respir Med 2009, 103:1633-1642.
28. Bousquet J., Cabrera P., Berkman N., Buhl R., Holgate S., Wenzel S., et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005, 60:302-308.
29. Chipps B., Buhl R., Beeh K.M., Fox H., Thomas K., Reisner C. Improvement in quality of life with omalizumab in patients with severe allergic asthma. Curr Med Res Opin 2006, 22:2201-2208.
30. Slavin R.G., Ferioli C., Tannenbaum S.J., Martin C., Blogg M., Lowe P.J. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations. J Allergy Clin Immunol 2009, 123:107-113.
31. Corren J., Casale T., Lanier B.Q., Blogg M., Reisner C., Gupta N. Omalizumab is well tolerated in adolescent/adult patients (>12 years) with moderate-to-severe persistent asthma. J Allergy Clin Immunol 2005, 115:S75.